COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
What members of Congress wrote in response to federal departments’ interpretation and guidance of health insurers’ COVID-19 testing payment obligations.
The National Healthcare Safety Network (NHSN) module was one of four pathways to reporting crucial COVID-19 data to HHS. The NHSN module was deactivated with the TeleTracking HHS Protect portal becoming the primary pathway for hospitals, hospital laboratories, and other healthcare facilities. The decision has met criticism.
Overview of what CVS Health announced and described as a comprehensive, customizable COVID-19 testing solution for employers and universities.
Large diagnostic clinical laboratories publicly share pain of surge in COVID-19 test demand. Recent lab pro letter urges “visibility into the process of supply allocation.” Smaller labs may be getting shortchanged.
Employee screening tools being developed by technology companies create unique opportunity for clinical laboratories to pursue strategic partnerships.
Points of interest in the Harvard analysis of observations in Wuhan, China, as early as August 2019, that share new insights into the origins of the COVID-19 pandemic.
What members of Congress wrote in response to federal departments’ interpretation and guidance of health insurers’ COVID-19 testing payment obligations.
The National Healthcare Safety Network (NHSN) module was one of four pathways to reporting crucial COVID-19 data to HHS. The NHSN module was deactivated with the TeleTracking HHS Protect portal becoming the primary pathway for hospitals, hospital laboratories, and other healthcare facilities. The decision has met criticism.
Overview of what CVS Health announced and described as a comprehensive, customizable COVID-19 testing solution for employers and universities.
Large diagnostic clinical laboratories publicly share pain of surge in COVID-19 test demand. Recent lab pro letter urges “visibility into the process of supply allocation.” Smaller labs may be getting shortchanged.
Employee screening tools being developed by technology companies create unique opportunity for clinical laboratories to pursue strategic partnerships.
Points of interest in the Harvard analysis of observations in Wuhan, China, as early as August 2019, that share new insights into the origins of the COVID-19 pandemic.
